Fluorescently labeled bevacizumab in human breast cancer - Defining the classification threshold

  • Maximilian Koch
  • , Johannes S. de Jong
  • , Jürgen Glatz
  • , Panagiotis Symvoulidis
  • , Laetitia E. Lamberts
  • , Arthur L.L. Adams
  • , Mariëtte E.G. Kranendonk
  • , A. G.T.T. van Scheltinga
  • , Michaela Aichler
  • , Liesbeth Jansen
  • , Jakob de Vries
  • , Marjolijn N. Lub-de Hooge
  • , Carolien P. Schröder
  • , Annelies Jorritsma-Smit
  • , Matthijs D. Linssen
  • , Esther de Boer
  • , Bert van der Vegt
  • , Wouter B. Nagengast
  • , Sjoerd G. Elias
  • , Sabrina Oliveira
  • Arjen J. Witkamp, Willem P.Th M. Mali, Elsken Van der Wall, P. Beatriz Garcia-Allende, Paul J. van Diest, Elisabeth G.E. de Vries, Axel Walch, Gooitzen M. van Dam, Vasilis Ntziachristos

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

Original languageEnglish
Title of host publicationEuropean Conference on Biomedical Optics, ECBO 2017
PublisherOptica Publishing Group (formerly OSA)
ISBN (Electronic)9781509067367
DOIs
StatePublished - 2017
EventEuropean Conference on Biomedical Optics, ECBO 2017 - Munich, Germany
Duration: 25 Jun 201729 Jun 2017

Publication series

NameOptics InfoBase Conference Papers
VolumePart F61-ECBO 2017
ISSN (Electronic)2162-2701

Conference

ConferenceEuropean Conference on Biomedical Optics, ECBO 2017
Country/TerritoryGermany
CityMunich
Period25/06/1729/06/17

Keywords

  • Clinical applications
  • Imaging systems
  • Medical and biological imaging

Fingerprint

Dive into the research topics of 'Fluorescently labeled bevacizumab in human breast cancer - Defining the classification threshold'. Together they form a unique fingerprint.

Cite this